scispace - formally typeset
Search or ask a question

Showing papers on "European union published in 2015"


Journal ArticleDOI
TL;DR: A bottom-up synthesis strategy for dispersible copper 1,4-benzenedicarboxylate MOF lamellae of micrometer lateral dimensions and nanometer thickness is presented and opens the door to ultrathin MOF-polymer composites for various applications.
Abstract: The research leading to these results has received funding (J.G., B.S.) from the European Research Council under the European Union’s Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement no. 335746, CrystEng-MOF-MMM. T.R. is grateful to TUDelft for funding. G.P. acknowledges the A. von Humboldt Foundation for a research grant. A.C., I.L. and F.X.L.i.X. thank Consolider-Ingenio 2010 (project MULTICAT) and the ‘Severo Ochoa’ programme for support. I.L. also thanks CSIC for a JAE doctoral grant.

1,649 citations


Journal ArticleDOI
TL;DR: This review provides a summary statement of recommended implementations of arterial spin labeling (ASL) for clinical applications and describes the major considerations and trade‐offs in implementing an ASL protocol and provides specific recommendations for a standard approach.
Abstract: This review provides a summary statement of recommended implementations of arterial spin labeling (ASL) for clinical applications. It is a consensus of the ISMRM Perfusion Study Group and the European ASL in Dementia consortium, both of whom met to reach this consensus in October 2012 in Amsterdam. Although ASL continues to undergo rapid technical development, we believe that current ASL methods are robust and ready to provide useful clinical information, and that a consensus statement on recommended implementations will help the clinical community to adopt a standardized approach. In this review, we describe the major considerations and trade-offs in implementing an ASL protocol and provide specific recommendations for a standard approach. Our conclusion is that as an optimal default implementation, we recommend pseudo-continuous labeling, background suppression, a segmented three-dimensional readout without vascular crushing gradients, and calculation and presentation of both label/control difference images and cerebral blood flow in absolute units using a simplified model.

1,617 citations



Journal ArticleDOI
TL;DR: In this paper, the authors summarize recent developments and the current knowledge of extracellular vesicles (EVs) and discuss safety and regulatory requirements that must be considered for pharmaceutical manufacturing and clinical application.
Abstract: Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types and participate in physiological and pathophysiological processes. EVs mediate intercellular communication as cell-derived extracellular signalling organelles that transmit specific information from their cell of origin to their target cells. As a result of these properties, EVs of defined cell types may serve as novel tools for various therapeutic approaches, including (a) anti-tumour therapy, (b) pathogen vaccination, (c) immune-modulatory and regenerative therapies and (d) drug delivery. The translation of EVs into clinical therapies requires the categorization of EV-based therapeutics in compliance with existing regulatory frameworks. As the classification defines subsequent requirements for manufacturing, quality control and clinical investigation, it is of major importance to define whether EVs are considered the active drug components or primarily serve as drug delivery vehicles. For an effective and particularly safe translation of EV-based therapies into clinical practice, a high level of cooperation between researchers, clinicians and competent authorities is essential. In this position statement, basic and clinical scientists, as members of the International Society for Extracellular Vesicles (ISEV) and of the European Cooperation in Science and Technology (COST) program of the European Union, namely European Network on Microvesicles and Exosomes in Health and Disease (ME-HaD), summarize recent developments and the current knowledge of EV-based therapies. Aspects of safety and regulatory requirements that must be considered for pharmaceutical manufacturing and clinical application are highlighted. Production and quality control processes are discussed. Strategies to promote the therapeutic application of EVs in future clinical studies are addressed.

954 citations


Journal ArticleDOI
TL;DR: In this article, a modified version of the Revised Universal Soil Loss Equation (RUSLE) model was used to estimate soil loss in Europe for the reference year 2010, within which the input factors (Rainfall erosivity, Soil erodibility, Cover-Management, Topography, Support practices) were modelled with the most recently available pan-European datasets.

814 citations


Journal ArticleDOI
07 May 2015-Nature
TL;DR: It is shown that a commonly used insecticide seed coating in a flowering crop can have serious consequences for wild bees, and the contribution of pesticides to the global decline of wild bees may have been underestimated.
Abstract: Understanding the effects of neonicotinoid insecticides on bees is vital because of reported declines in bee diversity and distribution and the crucial role bees have as pollinators in ecosystems and agriculture. Neonicotinoids are suspected to pose an unacceptable risk to bees, partly because of their systemic uptake in plants, and the European Union has therefore introduced a moratorium on three neonicotinoids as seed coatings in flowering crops that attract bees. The moratorium has been criticized for being based on weak evidence, particularly because effects have mostly been measured on bees that have been artificially fed neonicotinoids. Thus, the key question is how neonicotinoids influence bees, and wild bees in particular, in real-world agricultural landscapes. Here we show that a commonly used insecticide seed coating in a flowering crop can have serious consequences for wild bees. In a study with replicated and matched landscapes, we found that seed coating with Elado, an insecticide containing a combination of the neonicotinoid clothianidin and the non-systemic pyrethroid β-cyfluthrin, applied to oilseed rape seeds, reduced wild bee density, solitary bee nesting, and bumblebee colony growth and reproduction under field conditions. Hence, such insecticidal use can pose a substantial risk to wild bees in agricultural landscapes, and the contribution of pesticides to the global decline of wild bees may have been underestimated. The lack of a significant response in honeybee colonies suggests that reported pesticide effects on honeybees cannot always be extrapolated to wild bees.

812 citations


Journal ArticleDOI
TL;DR: The CHES trend file as discussed by the authors contains measures of national party positioning on European integration, ideology and several European Union (EU) and non-EU policies for 1999−2010, and explores basic trends on party positioning since 1999.
Abstract: This article reports on the 2010 Chapel Hill expert surveys (CHES) and introduces the CHES trend file, which contains measures of national party positioning on European integration, ideology and several European Union (EU) and non-EU policies for 1999−2010. We examine the reliability of expert judgments and cross-validate the 2010 CHES data with data from the Comparative Manifesto Project and the 2009 European Elections Studies survey, and explore basic trends on party positioning since 1999. The dataset is available at the CHES website.

762 citations


Journal ArticleDOI
TL;DR: This review summarizes the data published in the last decade regarding the application of advanced oxidation processes (AOPs) to treat priority compounds and certain other pollutants defined in this Directive, excluding the inorganic species.

760 citations


Journal ArticleDOI
TL;DR: A high and growing prevalence of COPD is suggested, both globally and regionally, and there is a need for governments, policy makers and international organizations to consider strengthening collaborations to address COPD globally.
Abstract: In a follow–up to the 2011 United Nations (UN) high level political declaration on non-communicable diseases (NCDs) [1], the World Health Assembly, in 2012, endorsed a new health goal (the “25 by 25 goal”), which focuses on reduction of premature deaths from COPD and other NCDs by 25% by the year 2025 [2]. Despite this initiative, experts have reported that COPD remains a growing [3], but neglected global epidemic [4]. The World Health Organization (WHO) estimated that there were about 62 million people with moderate to severe COPD in 2002, with the total number of COPD cases predicted to increase to about 200 million in 2010 [5,6]. According to the 2010 Global Burden of Disease (GBD) study, COPD was responsible for about 5% of global disability–adjusted life years – DALYs (76.7 million) – and 5% of total deaths (2.9 million) [7,8]. COPD is currently rated the fourth most common specific cause of death globally and predicted to be the third by 2030, in the absence of interventions that address the risks – especially tobacco smoking, exposures to combustion products of biomass fuels and environmental pollution [9,10]. The burden of COPD has been reported to be high in some high–income countries (HIC), particularly due to high prevalence of smoking in these settings [11]. For example, between years 2000 and 2010, about 4%–10% of adults were diagnosed with non–reversible and progressive airway obstruction (a basic feature of COPD) in population–based surveys across many European countries, with smoking indicated as a major risk [12]. The WHO has estimated that in many HIC up to 73% of COPD deaths are related to tobacco smoking [6]. The European Union (EU) reported that the direct cost from COPD was over 38.6 billion Euros in 2005, representing about 3% of total health care expenditure [13,14]. In the United States (US), over 2.7 million adults were estimated to have COPD in 2011, with about 135 000 deaths reported [15]. In 2010, the US government spent nearly US$ 49.9 billion on COPD, including 29.5 billion spent on direct health care, 8.0 billion on indirect morbidity and 12.4 billion on indirect mortality costs, respectively [15]. Meanwhile, it has been estimated that despite a high prevalence of COPD in some HIC, 90% of COPD deaths still occur in low– and middle–income countries (LMIC)in the future [4] and 40% of these deaths are attributable to smoking [6]. The burden in LMIC has been comparatively high owing to relatively low COPD awareness, challenges with COPD diagnosis and increased exposures to additional risk factors, especially combustion products of biomass fuels [16]. Salvi and colleagues reported that about 3 billion people globally are exposed to smoke from biomass fuel, compared to 1 billion people who smoke tobacco globally [17]. In many developing countries COPD is neglected by governments, physicians, experts and the pharmaceutical industry, although it's been identified as an important public health problem [4]. In the last two decades, the Burden of Obstructive Lung Disease (BOLD) initiative has been collecting country–specific data on the prevalence, risk factors and socioeconomic burden of COPD, using standardized and tested methods for conducting COPD surveys in the general population [18]. This is expected to provide governments of many nations with country–specific evidence on which to develop policy on COPD prevention and management [18]. As noted above, this initiative is yet to take a full effect in many LMIC [19]. In addition, spirometry (the gold standard for COPD diagnosis) is not widely available in many LMIC [16]. Even when it is there, professionals in LMIC are often not being trained properly on how to use spirometers or interpret spirometry results. There is concern that COPD burden has been underestimated, owing to over–reliance on doctor’s diagnosis, with many diagnoses not being based on spirometry and international diagnostic guidelines [20]. The lack of routine COPD data collation and effective health information management system in many LMIC also implies that these settings could have been grossly under–represented in global burden of COPD estimates [11]. Some global and regional estimates of COPD burden have been published [1,21–23]. However, despite the fact that COPD is now prevalent in both HIC and LMIC, experts have raised concerns that reliable estimates of COPD prevalence are still few in many parts of the world. Moreover, many of the estimates are based on varying definitions and diagnostic criteria of COPD [9]. Also, some of the current estimates were reported before the BOLD surveys in several countries, thereby failing to account for the additional spirometry–based epidemiological data from the BOLD surveys. There is a need for a revised and updated estimate of COPD prevalence across world regions. We conducted a systematic review of COPD prevalence based on spirometry data across world regions. Our aim was to provide global and regional prevalence rates of COPD that could facilitate adequate policy response in these regions.

746 citations


Journal ArticleDOI
TL;DR: McCann et al. as mentioned in this paper examined the smart specialization concept and explained the challenges involved in applying this originally sectoral concept to an explicitly spatial and regional setting, and the ways in which this might be achieved so as to make the concept suitable as a building block of a reformed European Union cohesion policy.
Abstract: McCann P. and Ortega-Argiles R. Smart specialization, regional growth and applications to European Union Cohesion policy, Regional Studies. The aim of this paper is to achieve two objectives. Firstly, it examines the smart specialization concept and explains the challenges involved in applying this originally sectoral concept to an explicitly spatial and regional setting. Secondly, it explains the ways in which this might be achieved so as to make the concept suitable as a building block of a reformed European Union cohesion policy.

723 citations


Journal ArticleDOI
TL;DR: In this paper, the authors applied a sociometabolic approach to assess the circularity of global material flows and found that only 4 gigatonnes per year (Gt/yr) of waste materials are recycled in the EU and only 1.5% of processed materials are used to provide energy and are thus not available for recycling.
Abstract: It is increasingly recognized that the growing metabolism of society is approaching limitations both with respect to sources for resource inputs and sinks for waste and emission outflows. The circular economy (CE) is a simple, but convincing, strategy, which aims at reducing both input of virgin materials and output of wastes by closing economic and ecological loops of resource flows. This article applies a sociometabolic approach to assess the circularity of global material flows. All societal material flows globally and in the European Union (EU-27) are traced from extraction to disposal and presented for main material groups for 2005. Our estimate shows that while globally roughly 4 gigatonnes per year (Gt/yr) of waste materials are recycled, this flow is of moderate size compared to 62 Gt/yr of processed materials and outputs of 41 Gt/yr. The low degree of circularity has two main reasons: First, 44% of processed materials are used to provide energy and are thus not available for recycling. Second, socioeconomic stocks are still growing at a high rate with net additions to stocks of 17 Gt/yr. Despite having considerably higher end-of-life recycling rates in the EU, the overall degree of circularity is low for similar reasons. Our results indicate that strategies targeting the output side (end of pipe) are limited given present proportions of flows, whereas a shift to renewable energy, a significant reduction of societal stock growth, and decisive eco-design are required to advance toward a CE

Journal ArticleDOI
TL;DR: It is found that schemes implemented after revision of the EU's agri-environmental programs in 2007 were not more effective than schemes implemented before revision and schemes aimed at areas out of production are more effective at enhancing species richness than those aimed at productive areas.
Abstract: Over half of the European landscape is under agricultural management and has been for millennia. Many species and ecosystems of conservation concern in Europe depend on agricultural management and are showing ongoing declines. Agri-environment schemes (AES) are designed partly to address this. They are a major source of nature conservation funding within the European Union (EU) and the highest conservation expenditure in Europe. We reviewed the structure of current AES across Europe. Since a 2003 review questioned the overall effectiveness of AES for biodiversity, there has been a plethora of case studies and meta-analyses examining their effectiveness. Most syntheses demonstrate general increases in farmland biodiversity in response to AES, with the size of the effect depending on the structure and management of the surrounding landscape. This is important in the light of successive EU enlargement and ongoing reforms of AES. We examined the change in effect size over time by merging the data sets of 3 recent meta-analyses and found that schemes implemented after revision of the EU's agri-environmental programs in 2007 were not more effective than schemes implemented before revision. Furthermore, schemes aimed at areas out of production (such as field margins and hedgerows) are more effective at enhancing species richness than those aimed at productive areas (such as arable crops or grasslands). Outstanding research questions include whether AES enhance ecosystem services, whether they are more effective in agriculturally marginal areas than in intensively farmed areas, whether they are more or less cost-effective for farmland biodiversity than protected areas, and how much their effectiveness is influenced by farmer training and advice? The general lesson from the European experience is that AES can be effective for conserving wildlife on farmland, but they are expensive and need to be carefully designed and targeted.

Journal ArticleDOI
TL;DR: In this paper, the authors provide a review of the policy framework for developing a bioeconomy in the European Union covering energy and climate, agriculture and forestry, industry and research, and estimate the current bio economy market at about € 2.4 billion including agriculture, food and beverage, agro-industrial products, fisheries and aquaculture, forestry, wood-based industry, biochemical, enzymes, biopharmaceutical, biofuels and bioenergy, using about 2 billion tonnes and employing 22 million persons.
Abstract: The European Commission has set a long-term goal to develop a competitive, resource efficient and low carbon economy by 2050. Bioeconomy is expected to play an important role in the low carbon economy. This paper provides a review of the policy framework for developing a bioeconomy in the European Union covering energy and climate, agriculture and forestry, industry and research. The Europe has a number of well-established traditional bio-based industries, ranging from agriculture, food, feed, fibre and forest-based industries. This paper proposes an analysis of the current status of bioeconomy in the European Union and worldwide until 2020 and beyond. We estimate the current bio economy market at about € 2.4 billion, including agriculture, food and beverage, agro-industrial products, fisheries and aquaculture, forestry, wood-based industry, biochemical, enzymes, biopharmaceutical, biofuels and bioenergy, using about 2 billion tonnes and employing 22 million persons. New sectors are emerging, such as biomaterials and green chemistry. The transition toward a bioeconomy will rely on the advancement in technology of a range of processes, on the achievement of a breakthrough in terms of technical performances and cost effectiveness and will depend on the availability of sustainable biomass.

Journal ArticleDOI
TL;DR: It is demonstrated that the non-parametric NOISeqBIO efficiently controls false discoveries in experiments with biological replication and outperforms state-of-the-art methods.
Abstract: European Union Seventh Framework Programme [FP7/2007-2013, 306000]; Spanish Ministry of Science and Innovation [MICINN, BIO2008-04638-E], in the framework of ERA-Net Pathogenomics; MICINN [DPI2008-06880-C03-03/DPI]. Funding for open access charge: University of Florida, Publication Funds.

Journal ArticleDOI
TL;DR: A broad catalogue of genetic mutations enable data from whole-genome sequencing to be used clinically to predict drug resistance, drug susceptibility, or to identify drug phenotypes that cannot yet be genetically predicted.
Abstract: Summary Background Diagnosing drug-resistance remains an obstacle to the elimination of tuberculosis. Phenotypic drug-susceptibility testing is slow and expensive, and commercial genotypic assays screen only common resistance-determining mutations. We used whole-genome sequencing to characterise common and rare mutations predicting drug resistance, or consistency with susceptibility, for all first-line and second-line drugs for tuberculosis. Methods Between Sept 1, 2010, and Dec 1, 2013, we sequenced a training set of 2099 Mycobacterium tuberculosis genomes. For 23 candidate genes identified from the drug-resistance scientific literature, we algorithmically characterised genetic mutations as not conferring resistance (benign), resistance determinants, or uncharacterised. We then assessed the ability of these characterisations to predict phenotypic drug-susceptibility testing for an independent validation set of 1552 genomes. We sought mutations under similar selection pressure to those characterised as resistance determinants outside candidate genes to account for residual phenotypic resistance. Findings We characterised 120 training-set mutations as resistance determining, and 772 as benign. With these mutations, we could predict 89·2% of the validation-set phenotypes with a mean 92·3% sensitivity (95% CI 90·7–93·7) and 98·4% specificity (98·1–98·7). 10·8% of validation-set phenotypes could not be predicted because uncharacterised mutations were present. With an in-silico comparison, characterised resistance determinants had higher sensitivity than the mutations from three line-probe assays (85·1% vs 81·6%). No additional resistance determinants were identified among mutations under selection pressure in non-candidate genes. Interpretation A broad catalogue of genetic mutations enable data from whole-genome sequencing to be used clinically to predict drug resistance, drug susceptibility, or to identify drug phenotypes that cannot yet be genetically predicted. This approach could be integrated into routine diagnostic workflows, phasing out phenotypic drug-susceptibility testing while reporting drug resistance early. Funding Wellcome Trust, National Institute of Health Research, Medical Research Council, and the European Union.

Journal ArticleDOI
TL;DR: Norovirus is shown to be responsible for most of the produce-related outbreaks, followed by Salmonella, which was the leading cause of multistate produce outbreaks in the United States and was the pathogen involved in the majority of sprouts-associated outbreaks.
Abstract: The consumption of fruit and vegetables continues to rise in the United States and European Union due to healthy lifestyle recommendations. Meanwhile, the rate of foodborne illness caused by the consumption of these products remains high in both regions, representing a significant public health and financial issue. This study addresses the occurrence of reported foodborne outbreaks associated with fresh fruits and vegetables consumption in the United States and European Union during the period 2004–2012, where data are available. Special attention is paid to those pathogens responsible for these outbreaks, the mechanisms of contamination, and the fresh produce vehicles involved. Norovirus is shown to be responsible for most of the produce-related outbreaks, followed by Salmonella. Norovirus is mainly linked with the consumption of salad in the United States and of berries in the European Union, as demonstrated by the Multiple Correspondence Analysis (MCA). Salmonella was the leading cause of mult...

Journal ArticleDOI
TL;DR: Employees who work long hours have a higher risk of stroke than those working standard hours; the association with coronary heart disease is weaker; these findings suggest that more attention should be paid to the management of vascular risk factors in individuals whoWork long hours.

Journal ArticleDOI
TL;DR: Rivastigmine is the second cholinesterase inhibitor marketed for symptomatic treatment of mild to moderately severe Alzheimer's dementia, and follows donepezil.
Abstract: Background Alzheimer's disease is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity. Other cholinesterase inhibitors, including rivastigmine, with superior properties in terms of specificity of action and lower risk of adverse effects have since been introduced. Rivastigmine has received approval for use in 60 countries including all member states of the European Union and the USA. Objectives To determine the clinical efficacy and safety of rivastigmine for patients with dementia of Alzheimer's type. Search methods We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group Specialized Register, on 2 March 2015 using the terms: Rivastigmine OR exelon OR ENA OR "SDZ ENA 713". ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases (Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS), numerous trial registries and grey literature sources. Selection criteria We included all unconfounded, double-blind, randomised, controlled trials in which treatment with rivastigmine was administered to patients with dementia of the Alzheimer's type for 12 weeks or more and its effects compared with those of placebo in a parallel group of patients, or where two formulations of rivastigmine were compared. Data collection and analysis One review author (JSB) applied the study selection criteria, assessed the quality of studies and extracted data. Main results A total of 13 trials met the inclusion criteria of the review. The trials had a duration of between 12 and 52 weeks. The older trials tested a capsule form with a dose of up to 12 mg/day. Trials reported since 2007 have tested continuous dose transdermal patch formulations delivering 4.6, 9.5 and 17.7 mg/day. Our main analysis compared the safety and efficacy of rivastigmine 6 to 12 mg/day orally or 9.5 mg/day transdermally with placebo. Seven trials contributed data from 3450 patients to this analysis. Data from another two studies were not included because of a lack of information and methodological concerns. All the included trials were multicentre trials and recruited patients with mild to moderate Alzheimer's disease with a mean age of about 75 years. All had low risk of bias for randomisation and allocation but the risk of bias due to attrition was unclear in four studies, low in one study and high in two studies. After 26 weeks of treatment rivastigmine compared to placebo was associated with better outcomes for cognitive function measured with the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) score (mean difference (MD) -1.79; 95% confidence interval (CI) -2.21 to -1.37, n = 3232, 6 studies) and the Mini-Mental State Examination (MMSE) score (MD 0.74; 95% CI 0.52 to 0.97, n = 3205, 6 studies), activities of daily living (SMD 0.20; 95% CI 0.13 to 0.27, n = 3230, 6 studies) and clinician rated global impression of changes, with a smaller proportion of patients treated with rivastigmine experiencing no change or a deterioration (OR 0.68; 95% CI 0.58 to 0.80, n = 3338, 7 studies). Three studies reported behavioural change, and there were no differences compared to placebo (standardised mean difference (SMD) -0.04; 95% CI -0.14 to 0.06, n = 1529, 3 studies). Only one study measured the impact on caregivers using the Neuropsychiatric Inventory-Caregiver Distress (NPI-D) scale and this found no difference between the groups (MD 0.10; 95% CI -0.91 to 1.11, n = 529, 1 study). Overall, participants who received rivastigmine were about twice as likely to withdraw from the trials (odds ratio (OR) 2.01, 95% CI 1.71 to 2.37, n = 3569, 7 studies) or to experience an adverse event during the trials (OR 2.16, 95% CI 1.82 to 2.57, n = 3587, 7 studies). Authors' conclusions Rivastigmine (6 to 12 mg daily orally or 9.5 mg daily transdermally) appears to be beneficial for people with mild to moderate Alzheimer's disease. In comparisons with placebo, better outcomes were observed for rate of decline of cognitive function and activities of daily living, although the effects were small and of uncertain clinical importance. There was also a benefit from rivastigmine on the outcome of clinician's global assessment. There were no differences between the rivastigmine group and placebo group in behavioural change or impact on carers. At these doses the transdermal patch may have fewer side effects than the capsules but has comparable efficacy. The quality of evidence is only moderate for all of the outcomes reviewed because of a risk of bias due to dropouts. All the studies with usable data were industry funded or sponsored. This review has not examined economic data.

Journal ArticleDOI
TL;DR: A comprehensive review of the state-of-the-art on mobile health services and applications is presented in this paper, where the authors present a deep analysis of the top and novel m-Health services and application proposed by industry.

Journal ArticleDOI
TL;DR: This work proposes to farmers, advisors, and researchers a dynamic and flexible approach that accounts for the diversity of farming situations and the complexities of agroecosystems and that can improve the resilience of cropping systems and the authors' capacity to adapt crop protection to local realities.
Abstract: The use of pesticides made it possible to increase yields, simplify cropping systems, and forego more complicated crop protection strategies. Over-reliance on chemical control, however, is associated with contamination of ecosystems and undesirable health effects. The future of crop production is now also threatened by emergence of pest resistance and declining availability of active substances. There is therefore a need to design cropping systems less dependent on synthetic pesticides. Consequently, the European Union requires the application of eight principles (P) of Integrated Pest Management that fit within sustainable farm management. Here, we propose to farmers, advisors, and researchers a dynamic and flexible approach that accounts for the diversity of farming situations and the complexities of agroecosystems and that can improve the resilience of cropping systems and our capacity to adapt crop protection to local realities. For each principle (P), we suggest that (P1) the design of inherently robust cropping systems using a combination of agronomic levers is key to prevention. (P2) Local availability of monitoring, warning, and forecasting systems is a reality to contend with. (P3) The decision-making process can integrate cropping system factors to develop longer-term strategies. (P4) The combination of non-chemical methods that may be individually less efficient than pesticides can generate valuable synergies. (P5) Development of new biological agents and products and the use of existing databases offer options for the selection of products minimizing impact on health, the environment, and biological regulation of pests. (P6) Reduced pesticide use can be effectively combined with other tactics. (P7) Addressing the root causes of pesticide resistance is the best way to find sustainable crop protection solutions. And (P8) integration of multi-season effects and trade-offs in evaluation criteria will help develop sustainable solutions.

Journal ArticleDOI
TL;DR: The post-Maastricht period is marked by an integration paradox as discussed by the authors, where the basic constitutional features of the European Union have remained stable, EU activity has expanded to an unprecedented degree.
Abstract: The post-Maastricht period is marked by an integration paradox. While the basic constitutional features of the European Union have remained stable, EU activity has expanded to an unprecedented degree. This form of integration without supranationalism is no exception or temporary deviation from traditional forms of European integration. Rather, it is a distinct phase of European integration, what is called ‘the new intergovernmentalism’ in this article. This approach to post-Maastricht integration challenges theories that associate integration with transfers of competences from national capitals to supranational institutions and those that reduce integration to traditional socioeconomic or security-driven interests. This article explains the integration paradox in terms of transformations in Europe's political economy, changes in preference formation and the decline of the ‘permissive consensus’. It presents a set of six hypotheses that develop further the main claims of the new intergovernmentalism and that can be used as a basis for future research.


Journal ArticleDOI
TL;DR: In this paper, a comprehensive review of the state of the art on mobile health services and applications is presented, and a discussion considering the European Union and United States approaches addressing the m-Health paradigm and directives already published is also considered.


Journal ArticleDOI
TL;DR: The authors found that students in countries outside Western Europe showed a greater interest in school science, in careers related to science and in extracurricular activities related to Science than did Western European students.
Abstract: International studies have shown that interest in science and technology among primary and secondary school students in Western European countries is low and seems to be decreasing. In many countries outside Europe, and especially in developing countries, interest in science and technology remains strong. As part of the large-scale European Union funded ‘Science Education for Diversity’ project, a questionnaire probing potential reasons for this difference was completed by students in the UK, Netherlands, Turkey, Lebanon, India and Malaysia. This questionnaire sought information about favourite courses, extracurricular activities and views on the nature of science. Over 9,000 students aged mainly between 10 and 14 years completed the questionnaire. Results revealed that students in countries outside Western Europe showed a greater interest in school science, in careers related to science and in extracurricular activities related to science than did Western European students. Non-European students were also more likely to hold an empiricist view of the nature of science and to believe that science can solve many problems faced by the world. Multilevel analysis revealed a strong correlation between interest in science and having such a view of the Nature of Science.

Journal ArticleDOI
TL;DR: The erosivity density (erosivity normalised to annual precipitation amounts) was the highest in Mediterranean regions which implies high risk for erosive events and floods, and Gaussian Process Regression has been used to interpolate the R-factor station values to a European rainfall erOSivity map at 1 km resolution.

Journal ArticleDOI
TL;DR: U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment, and is well suited to identify asthma phenotypes using the array of "omic" datasets that are at the core of this systems medicine approach.
Abstract: U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach.This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements.Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p<0.001), with worse quality of life, and higher levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-oesophageal reflux with lower lung function. Sputum eosinophil count was higher in severe asthma compared to mild/moderate asthma (median count 2.99% versus 1.05%; p=0.004) despite treatment with higher doses of inhaled and/or oral corticosteroids.Consistent with other severe asthma cohorts, U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment. It is well suited to identify asthma phenotypes using the array of "omic" datasets that are at the core of this systems medicine approach.

Journal ArticleDOI
John C. Chambers, Marie Loh1, Marie Loh2, Marie Loh3, Benjamin Lehne1, Alexander W. Drong4, Jennifer Kriebel, Valeria Motta5, Simone Wahl, Hannah R Elliott1, Hannah R Elliott6, Federica Rota5, William R. Scott7, William R. Scott1, Weihua Zhang1, Weihua Zhang8, Sian-Tsung Tan8, Sian-Tsung Tan7, Gianluca Campanella1, Marc Chadeau-Hyam1, Loic Yengo9, Loic Yengo10, Rebecca C Richmond6, Martyna Adamowicz-Brice11, Uzma Afzal1, Uzma Afzal8, Kiymet Bozaoglu12, Zuan Yu Mok13, Hong Kiat Ng13, François Pattou9, François Pattou14, Holger Prokisch15, Michelle Ann Rozario13, Letizia Tarantini5, James Abbott1, Mika Ala-Korpela, Benedetta Albetti5, Ole Ammerpohl16, Pier Alberto Bertazzi5, Christine Blancher17, R. Caiazzo12, R. Caiazzo6, John Danesh18, Tom R. Gaunt6, Simon de Lusignan19, Christian Gieger, Thomas Illig20, Sujeet Jha21, Simon Jones19, Jeremy B. M. Jowett12, Antti J. Kangas2, Anuradhani Kasturiratne22, Norihiro Kato, Navaratnam Kotea23, Sudhir Kowlessur, Janne Pitkäniemi24, Prakash P Punjabi25, Danish Saleheen26, Danish Saleheen18, Clemens Schafmayer, Pasi Soininen27, Pasi Soininen2, E-Shyong Tai13, Barbara Thorand, Jaakko Tuomilehto24, Ananda R. Wickremasinghe22, Soterios A. Kyrtopoulos, Timothy J. Aitman11, Christian Herder28, Jochen Hampe29, Stéphane Cauchi10, Stéphane Cauchi9, Caroline L Relton6, Philippe Froguel, Richie Soong13, Paolo Vineis1, Marjo-Riitta Järvelin, James Scott7, Harald Grallert, Valentina Bollati5, Paul Elliott1, Mark I. McCarthy30, Mark I. McCarthy4, Mark I. McCarthy17, Jaspal S. Kooner 
TL;DR: A nested case-control study of DNA methylation in Indian Asians and Europeans with incident type 2 diabetes who were identified from the 8-year follow-up of 25 372 participants in the London Life Sciences Prospective Population study.

Journal ArticleDOI
TL;DR: The goal of this paper is to identify the major modifiable risk factors for dementia as a first step in developing an effective preventive strategy and promoting healthy late life cognitive functioning.
Abstract: The In-MINDD project is funded by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 304979 (“In-MINDD”). The project commenced in November 2012 and has a duration of three years. K. A. is funded by NHMRC Fellowship APP1002560. The ESPRIT Project is funded by a non-conditional grant from Novartis and the French National Research Agency (ANR).

Journal ArticleDOI
TL;DR: Examination of the available evidence on the economic burden of MSDs on work across Europe highlights areas of policy, clinical and employment practice which might improve work outcomes for individuals and families and reduce the economic and social costs of MSD.
Abstract: Musculoskeletal disorders (MSDs) are the leading cause of work disability, sickness absence from work, ‘presenteeism’ and loss of productivity across all the European Union (EU) member states. It is estimated that the total cost of lost productivity attributable to MSDs among people of working age in the EU could be as high as 2% of gross domestic product (GDP). This paper examines the available evidence on the economic burden of MSDs on work across Europe and highlights areas of policy, clinical and employment practice which might improve work outcomes for individuals and families and reduce the economic and social costs of MSDs.